UAB Hematology Review 2021
Avatar

Frontline Daratumumab in MM: D-VTd vs. VTd, D-RVd vs. RVd in Transplant-Eligible Disease, Dara-KRd; Dara+/-VMP, Dara+Len/Dex vs. Len Alone in Transplant-Ineligible Disease

By UAB Hematology Review 2021 FEATURING Susan Bal
By UAB Hematology Review 2021 FEATURING Susan Bal
89 views
March 16, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
06:19
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Dara-KRd in NDMM Without ASCT - Final Analy…

Feat. B. Derman
49:01
Scripps MD Anderson Cancer Center

Current Summary of the Multiple Myeloma Treatment Landscape

Feat. R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
16:28
Total Health

Multiple Myeloma: A New Risk-Adapted Approach

Feat. J. Chandler
08:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…

Feat. N. Joseph
11:38
Heinz Ludwig

Maintenance Therapy in Myeloma: Which Agent and for How Long?

31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
05:47
Meletios Dimopoulos

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…

21:51
Moffitt Cancer Center

State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…

Feat. A. Grajales-Cruz
06:23
Integrity Continuing Education

ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VR…

Feat. O. Landgren
13:18
Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak
04:15
Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou